Telatinib Effect on Biomarker is Associated With More Than Six Months Improvement in Progression-Free Survival for Stomach Cancer Patients SAN FRANCISCO, Nov. 12, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a clinical stage biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of...

ACT Biotech's Telatinib Demonstrates Significant Progress in Stomach Cancer Treatment; Phase 2 Data to be Presented at ASCO SAN FRANCISCO, June 2, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced...

ACT BIOTECH to Present Significant Progress in Stomach Cancer Treatment at ASCO SAN FRANCISCO, May 19, 2011 (GLOBE NEWSWIRE) -- ACT BIOTECH, Inc today announced that it will present encouraging results on the telatinib Phase 2 clinical trial in patients with advanced stomach...

ACT Biotech Files Special Protocol Assessment With FDA for Phase 3 Trial of Telatinib for Front-Line Treatment of Stomach Cancer SAN FRANCISCO, Feb. 28, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced...

Phase 2 Data in Stomach Cancer Show Telatinib's Potent Antiangiogenic Activity SAN FRANCISCO, Jan. 20, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today...